Drug Trial Radar · NCT01618591
Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea
Last checked: Nov 19, 2026Latest source record: Nov 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
384
Actual
Start
Sep 2012
Primary completion
Mar 2016
Study completion Mar 2016
Sponsor
- Lead sponsor
- Uniformed Services University of the Health SciencesFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Navy Bureau of Medicine and Surgery; Ministry of Defence, United Kingdom; Naval Medical Research Center; Naval Medical Research Unit- 3; United States Army Medical Unit - Kenya; United States Naval Medical Center, Portsmouth; Naval Medical Research Unit- 6
- First posted
- Jun 13, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial is to develop the evidence on relative efficacy of 3 available single-dose loperamide adjuncted regimens for watery diarrhea and a single-dose regimen, with and without loperamide, for dysentery/febrile diarrhea required for informing decisions among these regimens. Information from this study will be used to develop management guidelines for the diagnosis and management of travelers' diarrhea (TD) among deployed United States and United Kingdom military personnel.
Conditions
- Acute Watery Diarrhea
- Dysentery/Febrile Diarrhea
Interventions
Single dose rifaximin 1650 mgDrug
Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Single dose azithromycin 500 mgDrug
Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Single dose levofloxacin 500 mgDrug
Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Single dose azithromycin 1000 mg plus loperamideDrug
Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Single dose azithromycin 1000 mg plus placeboDrug
Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Cure - Acute Watery Diarrhea groupTime frame: 24 hours
- Clinical Cure - Acute Dysentery/Febrile Diarrhea groupTime frame: 48 hours
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
UK Role 3 Joint Force Hospital
Camp Bastion Air Base, Afghanistan
U.S. Naval Expeditionary Base
Camp Lemonnier, Djibouti
Joint Task Force - Bravo
Soto Cano Air Base, Honduras
British Army Training Unit Kenya
Nanyuki, Kenya
Armed Forces Research Institute of Medical Sciences
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.